Prediction of therapy response in ovarian cancer: Where are we now?

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521:489–494.
   PubMed Web of Science ®Google Scholar
• Tewari K, Monk B. Chapter 4. Managing the patient. In: The 21st century handbook of clinical ovarian cancer. Switzerland: Springer; 2015. p. 31–60.
   Google Scholar
• Petrillo M, Nero C, Amadio G, et al. Targeting the hallmarks of ovarian cancer: the big picture. Gynecol Oncol. 2016;142:176–183.
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–1337.
   PubMed Web of Science ®Google Scholar
• El Bairi K, Kandhro AH, Gouri A, et al. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell Oncol. 2017;40:105–118.
   Web of Science ®Google Scholar
• Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci. 2014;51:160–171.
   PubMed Web of Science ®Google Scholar
• Cao L, Zhu W, Wagar EA, et al. Biomarkers for monitoring chemotherapy-induced cardiotoxicity. Crit Rev Clin Lab Sci. 2017;54:87–101.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Crown J. Precision treatment for cancer: role of prognostic and predictive markers. Crit Rev Clin Lab Sci. 2014;51:30–45.
   PubMed Web of Science ®Google Scholar
• Braicu EI, Sehouli J, Richter R, et al. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011;105:1818–1824.
   PubMed Web of Science ®Google Scholar
• Sung PL, Chang YH, Chao KC, et al. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol. 2014;133:147–154.
   PubMed Web of Science ®Google Scholar
• Lee AW, Templeman C, Stram DA, et al. Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril. 2016;105:35–43.e1–10.
   PubMed Web of Science ®Google Scholar
• Mogensen JB, Kjær SK, Mellemkjær L, et al. Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol. 2016;143:87–92.
   PubMed Web of Science ®Google Scholar
• Corzo C, Iniesta MD, Patrono MG, et al. The role of fallopian tubes in the development of ovarian cancer. J Minim Invasive Gynecol. 2017;24:230–234.
   PubMed Web of Science ®Google Scholar
• Auersperg N. Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Gynecol Oncol. 2013;130:246–251.
   PubMed Web of Science ®Google Scholar
• Helder-Woolderink JM, Blok EA, Vasen HF, et al. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer. 2016;55:65–73.
   PubMed Web of Science ®Google Scholar
• Pradeep S, Kim SW, Wu SY, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26:77–91.
   PubMed Web of Science ®Google Scholar
• Paduch R. The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol (Dordr). 2016;39:397–410.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhang YWM, Yang XM, et al. Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal–epithelial transition. Cancer Lett. 2015;363:71–82.
   PubMed Web of Science ®Google Scholar
• Luo Z, Wang Q, Lau WB, et al. Tumor microenvironment: the culprit for ovarian cancer metastasis? Cancer Lett. 2016;377:174–182.
   PubMed Web of Science ®Google Scholar
• Gavalas NG, Liontos M, Trachana SP, et al. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci. 2013;14:15885–15909.
   PubMed Web of Science ®Google Scholar
• Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273–282.
   PubMed Web of Science ®Google Scholar
• Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 2012;72:2701–2704.
   PubMed Web of Science ®Google Scholar
• Vang RMS, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267–282.
   PubMed Web of Science ®Google Scholar
• Wu R, Baker SJ, Hu TC, et al. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol. 2013;182:1391–1399.
   PubMed Web of Science ®Google Scholar
• Maradeo ME, Cairns P. Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett. 2011;585:2112–2120.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol. 2010;28:3545–3548.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–120.
   PubMed Web of Science ®Google Scholar
• Sonnenblick A, De Azambuja E, Azim Jr, et al. An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol. 2015;12:27–41.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016;115:1157–1173.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7:508–519.
   PubMed Web of Science ®Google Scholar
• McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014;27:128–134.
   PubMed Web of Science ®Google Scholar
• Martins FC, Santiago I, Trinh A, et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 2014;15:526.
   PubMed Web of Science ®Google Scholar
• Bast RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22(Suppl 8):5–15.
   Google Scholar
• Gest C, Mirshahi P, Li H, et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett. 2012;317:207–217.
   PubMed Web of Science ®Google Scholar
• Beauchamp MC, Yasmeen A, Knafo A, et al. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010;2010:257058.
   PubMedGoogle Scholar
• Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol. 2012;84:314–326.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014;132:496–505.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. JCO. 2014;32:1302–1308.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387:1066–1074.
   PubMed Web of Science ®Google Scholar
• Ivy SP, Liu JF, Lee JM, et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016;25:597–611.
   PubMed Web of Science ®Google Scholar
• Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16:1515–1524.
   PubMed Web of Science ®Google Scholar
• Al Wadi K, Ghatage P. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer. Expert Opin Pharmacother. 2016;17:853–860.
   PubMed Web of Science ®Google Scholar
• Varga A, Piha-Paul SA, Ott PA, et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J Clin Oncol. 2015;33(suppl; abstr 5510).
   Google Scholar
• Emens LA, Kok M, Ojalvo LS. Targeting the programmed cell death-1 pathway in breast and ovarian cancer. Curr Opin Obstet Gynecol. 2016;28:142–147.
   PubMed Web of Science ®Google Scholar
• Yeung TL, Leung CS, Wong KK, et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013;73:5016–5028.
   PubMed Web of Science ®Google Scholar
• Nishio H, Yaguchi T, Sugiyama J, et al. Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer. 2014;110:2965–2974.
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Kuroda H, Takahashi R, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137:173–179.
   PubMed Web of Science ®Google Scholar
• Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011;104:1241–1245.
   PubMed Web of Science ®Google Scholar
• Pautier P, Joly F, Kerbrat P, et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol. 2010;116:157–162.
   PubMed Web of Science ®Google Scholar
• Vergote IB, Jimeno A, Joly F, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European organisation for research and treatment of cancer—gynaecological cancer group, and gynecologic cancer intergroup study. JCO. 2014;32:320–326.
   PubMed Web of Science ®Google Scholar
• Hirte H, Oza A, Swenerton K, et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol. 2010;118:308–312.
   PubMed Web of Science ®Google Scholar
• Warner E, Liebes L, Levinson B, et al. Continuous infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness. Oncologist. 2014;19:250.
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. JCO. 2003;21:283–290.
   PubMed Web of Science ®Google Scholar
• Kaldawy A, Segev Y, Lavie O, et al. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143:433–438.
   PubMed Web of Science ®Google Scholar
• Jones S, Wang TL, Shih IM. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228–231.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Yamazaki M, Takahashi H. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Am J Clin Pathol. 2015;144:452–463.
   PubMed Web of Science ®Google Scholar
• Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313.
   PubMed Web of Science ®Google Scholar
• Tone AA, McConechy MK, Yang W. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 2014;14:982.
   PubMed Web of Science ®Google Scholar
• Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013;95:235–241.
   PubMed Web of Science ®Google Scholar
• Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229:111–120.
   PubMed Web of Science ®Google Scholar
• Tang MK, Wong AS. Exosomes: emerging biomarkers and targets for ovarian cancer. Cancer Lett. 2015;367:26–33.
   PubMed Web of Science ®Google Scholar
• Burton E, Chase D, Yamamoto M, et al. Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach. Gynecol Oncol. 2011;120:29–32.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Mancini M, Di Rocco R, et al. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol. 2012;2012:613980.
   PubMedGoogle Scholar
• Vitale SG, Marilli I, Lodato M, et al. The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. Updates Surg. 2013;65:265–270.
   PubMedGoogle Scholar
• Teo MC. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer. Curr Opin Obstet Gynecol. 2014;26:3–8.
   PubMed Web of Science ®Google Scholar
• Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374:738–748.
   PubMed Web of Science ®Google Scholar
• Colombo N, Conte PF, Pignata S, et al. Bevacizumab in ovarian cancer: focus on clinical data and future perspectives. Crit Rev Oncol Hematol. 2016;97:335–348.
   PubMed Web of Science ®Google Scholar
• Heitz F, Harter P, Barinoff J, et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther. 2012;29:723–735.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19:961–968.
   PubMed Web of Science ®Google Scholar
• Dizon DS. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer? Am J Clin Oncol. 2013;36:519–525.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs. 2015;20:331–346.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–2496.
   PubMed Web of Science ®Google Scholar
• du Bois A, Floquet A, Kim JW. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374–3382.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799–808.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Dalton H, Farley JH, et al. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013;86:161–175.
   PubMed Web of Science ®Google Scholar
• El Bairi K, EL-Meghawry EA, Rahman H, et al. Natural products against cancer angiogenesis. Tumour Biol. 2016;37:14513–14536.
   PubMed Web of Science ®Google Scholar
• Teplinsky E, Herzog TJ. The efficacy of trabectedin in treating ovarian cancer. Expert Opin Pharmacother. 2017;18:313–323.
   PubMed Web of Science ®Google Scholar
• Munroe M, Kolesar J. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Am J Health Syst Pharm. 2016;73:1037–1041.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. In: Zhou J, editor. Multi-drug resistance in cancer. Methods in Molecular Biology, NY, USA: Humana Press. vol. 596; 2010. p. 47–76.
   Google Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769–1792.
   PubMed Web of Science ®Google Scholar
• Borley J, Brown R. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med. 2015;47:359–369.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–516.
   PubMed Web of Science ®Google Scholar
• Brown R, Curry E, Magnani L, et al. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14:747–753.
   PubMed Web of Science ®Google Scholar
• Ffrench B, Gasch C, O'Leary JJ, et al. Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Mol Cancer. 2014;13:262.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726.
   PubMed Web of Science ®Google Scholar
• Rivlin N, Brosh R, Oren M, et al. Mutations in the p53 tumor suppressor gene important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466–474.
   PubMedGoogle Scholar
• Montoni A, Robu M, Pouliot E, et al. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol. 2013;4:18.
   PubMed Web of Science ®Google Scholar
• Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract. 2016;3:3.
   PubMedGoogle Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–5599.
   PubMed Web of Science ®Google Scholar
• Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013;4:28.
   PubMed Web of Science ®Google Scholar
• Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111–1115.
   PubMed Web of Science ®Google Scholar
• Johnson N, Johnson SF, Yao W, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci USA. 2013;110:17041–17046.
   PubMed Web of Science ®Google Scholar
• Martin RW, Orelli BJ, Yamazoe M, et al. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res. 2007;67:9658–9665.
   PubMed Web of Science ®Google Scholar
• Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015;521:541–544.
   PubMed Web of Science ®Google Scholar
• Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly (ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA. 2011;108:3406–3411.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan A, Sawers L, Gannon AL, et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016;115:431–441.
   PubMed Web of Science ®Google Scholar
• Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997;53:461–470.
   PubMed Web of Science ®Google Scholar
• Wang YC, Juric D, Francisco B, et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer. 2006;45:365–374.
   PubMed Web of Science ®Google Scholar
• Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6:201.
   PubMed Web of Science ®Google Scholar
• Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997;15:45–52.
   PubMed Web of Science ®Google Scholar
• Drummond JT, Anthoney A, Brown R, et al. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem. 1996;271:19645–19648.
   PubMed Web of Science ®Google Scholar
• Strathdee G, MacKean MJ, Illand M, et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335–2341.
   PubMed Web of Science ®Google Scholar
• Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010;30:3223–3232.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 2000;60:5815–5824.
   PubMed Web of Science ®Google Scholar
• Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307.
   PubMed Web of Science ®Google Scholar
• Silber JR, Blank A, Bobola MS, et al. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Nat Rev Cancer. 1999;5:807–814.
   Google Scholar
• Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851–3857.
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793–797.
   PubMed Web of Science ®Google Scholar
• Teodoridis JM, Hall J, Marsh S, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005;65:8961–8967.
   PubMed Web of Science ®Google Scholar
• Wang N, Zhang H, Yao Q, et al. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.
   PubMed Web of Science ®Google Scholar
• Coley HM, Safuwan NA, Chivers P, et al. The cyclin-dependent kinase inhibitor p57Kip2 is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. Br J Cancer. 2012;106:482–489.
   PubMed Web of Science ®Google Scholar
• Strathdee G, Vass JK, Oien KA, et al. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol. 2005;97:898–903.
   PubMed Web of Science ®Google Scholar
• Lum E, Vigliotti M, Banerjee N, et al. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. Gynecol Oncol. 2013;130:369–376.
   PubMed Web of Science ®Google Scholar
• Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770–776.
   PubMed Web of Science ®Google Scholar
• White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12:401–410.
   PubMed Web of Science ®Google Scholar
• Cook KL, Wärri A, Soto-Pantoja DR, et al. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER + breast cancer. Clin Cancer Res. 2014;20:3222–3232.
   PubMed Web of Science ®Google Scholar
• Shang Y, Cai X, Fan D. Roles of epithelial–mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets. 2013;13:915–929.
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751.
   PubMed Web of Science ®Google Scholar
• Alkema NG, Wisman GB, van der Zee AG, et al. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat. 2016;24:55–69.
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting epithelial–mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21:965. doi: 10.3390/molecules21070965.
   PubMed Web of Science ®Google Scholar
• Zhu X, Shen H, Yin X, et al. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2016;35:323–332.
   PubMed Web of Science ®Google Scholar
• Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012;12:699–709.
   PubMed Web of Science ®Google Scholar
• Giuliano S, Pagès G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2013;95:1110–1119.
   PubMed Web of Science ®Google Scholar
• Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecol Oncol. 2016;141:80–85.
   PubMed Web of Science ®Google Scholar
• Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002;87:8–16.
   PubMed Web of Science ®Google Scholar
• Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer. 2006;16:194–201.
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Krivak TC, Fader AN, et al. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol. 2010;203:e1–e6.
   PubMed Web of Science ®Google Scholar
• O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol. 2001;83:334–342.
   PubMed Web of Science ®Google Scholar
• Rutherford T, Orr J Jr, Grendys E Jr, et al. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol. 2013;131:362–367.
   PubMed Web of Science ®Google Scholar
• Krivak TC, Lele S, Richard S, et al. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Am J Obstet Gynecol. 2014;211:68.e1–68.
   Web of Science ®Google Scholar
• Tian C, Sargent DJ, Krivak TC, et al. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer. 2014;111:843–850.
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Krivak TC, Mucenski JW, et al. Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. Am J Obstet Gynecol. 2010;203:160.e1–167.
   Web of Science ®Google Scholar
• Deng J, Wang L, Ni J, et al. Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Expert Rev Proteomics. 2016;13:905–915. doi: 10.1080/14789450.2016.1233065.
   PubMed Web of Science ®Google Scholar
• Wasinger VC, Zeng M, Yau Y. Current status and advances in quantitative proteomic mass spectrometry. Int J Proteomics. 2013;2013:180605. doi: 10.1155/2013/180605.
   PubMedGoogle Scholar
• Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129.
   PubMed Web of Science ®Google Scholar
• Vasudev NS, Trigonis I, Cairns DA, et al. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011;284:221–227.
   PubMed Web of Science ®Google Scholar
• Rustin GJ. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011;22(Suppl 8):45–48.
   Google Scholar
• Prat A, Parera M, Adamo B, et al. Risk of recurrence during follow up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol. 2009;20:294–297.
   PubMed Web of Science ®Google Scholar
• Han LY, Karavasilis V, Hagen T, et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. EUR J Cancer. 2010;46:1359–1364.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–1163.
   PubMed Web of Science ®Google Scholar
• Verheijen RHM, Cibula D, Zola P, et al. Cancer antigen 125: lost to follow-up? A European Society Of Gynaecological Oncology Consensus Statement. Int J Gynecol Cancer. 2012;22:170–174.
   PubMed Web of Science ®Google Scholar
• Van der Zee AG, Colombo N, Gitsch G, et al. ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22:175.
   PubMed Web of Science ®Google Scholar
• Esselen KM, Cronin AM, Bixel K, et al. Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer. JAMA Oncol. 2016;2:1427–1433.
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–46.
   PubMed Web of Science ®Google Scholar
• Moore RG, Hawkins DM, Miller MC, et al. Combining clinical assessment and the risk of ovarian malignancy algorithm for the prediction of ovarian cancer. Gynecol Oncol. 2014;135:547–551.
   PubMed Web of Science ®Google Scholar
• Chudecka-Głaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta. 2015;440:143–151.
   PubMed Web of Science ®Google Scholar
• Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118(2 Pt 1):280–288.
   PubMed Web of Science ®Google Scholar
• ROMA™ (HE4 EIA + ARCHITECT CA 125 IITM) prescribing information. Fujirebio Diagnostics, Inc.; 2011.
   Google Scholar
• ROMA 510(k) summary: K103358. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103358.pdf
   Google Scholar
• Steffensen KD, Waldstrøm M, Brandslund I, et al. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012;22:1474–1482.
   PubMed Web of Science ®Google Scholar
• Angioli R, Capriglione S, Aloisi A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014;35:7009–7015.
   PubMed Web of Science ®Google Scholar
• Vallius T, Hynninen J, Auranen A, et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumor Biol. 2014;35:12389–12395.
   PubMed Web of Science ®Google Scholar
• Pelissier A, Roulot A, Guéry B, et al. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. J Ovarian Res. 2016;9:61.
   PubMed Web of Science ®Google Scholar
• Chudecka-Głaz AM, Cymbaluk-Płoska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:1.
   PubMed Web of Science ®Google Scholar
• Yu KH, Levine DA, Zhang H, et al. Predicting ovarian cancer patients’ clinical response to platinum-based chemotherapy by their tumor proteomic signatures. J Proteome Res. 2016;15:2455–2465.
   PubMed Web of Science ®Google Scholar
• Lane D, Matte I, Garde-Granger P, et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15:492.
   PubMed Web of Science ®Google Scholar
• Elstrand MB, Kleinberg L, Kohn EC, et al. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl 2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol. 2009;28:211–221.
   PubMed Web of Science ®Google Scholar
• Dorn J, Harbeck N, Kates R, et al. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol. 2011;22:877–883.
   PubMed Web of Science ®Google Scholar
• Gouri A, Dekaken A, El Bairi K, et al. Plasminogen activator system and breast cancer: potential role in therapy decision making and precision medicine. Biomark Insights. 2016;11:105–111.
   PubMed Web of Science ®Google Scholar
• Xu L, Cai J, Yang Q, et al. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol. 2013;139:1257–1277.
   PubMed Web of Science ®Google Scholar
• Yan XD, Pan LY, Yuan Y, et al. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res. 2007;6:772–780.
   PubMed Web of Science ®Google Scholar
• Chen M, Huang H, He H, et al. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines. Cancer Sci. 2015;106:1075–1083.
   PubMed Web of Science ®Google Scholar
• Dai Z, Yin J, He H, et al. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics. 2010;10:3789–3799.
   PubMed Web of Science ®Google Scholar
• Di Michele M, Marcone S, Cicchillitti L, et al. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. J Proteomics. 2010;73:879–898.
   PubMed Web of Science ®Google Scholar
• Cicchillitti L, Di Michele M, Urbani A, et al. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res. 2009;8:1902–1912.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei S, Ma Y, et al. Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer. Theranostics. 2014;4:1164–1175.
   PubMed Web of Science ®Google Scholar
• Cheng WF, Huang CY, Chang MC, et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. 2009;100:1144–1153.
   PubMed Web of Science ®Google Scholar
• Stewart JJ, White JT, Yan X, et al. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2006;5:433–443.
   PubMed Web of Science ®Google Scholar
• Hetland TE, Hellesylt E, Flørenes VA, et al. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol. 2011;42:1019–1026.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Takano M, Iwaya K, et al. X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer. 2014;110:2881–2886.
   PubMed Web of Science ®Google Scholar
• Koti M, Gooding RJ, Nuin P, et al. Identification of the IGF1/PI3K/NFκB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013;13:549.
   PubMed Web of Science ®Google Scholar
• Gong F, Peng X, Zeng Z, et al. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol Cell Biochem. 2011;348:141–147.
   PubMed Web of Science ®Google Scholar
• Furlong F, Fitzpatrick P, O'Toole S, et al. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol. 2012;226:746–755.
   PubMed Web of Science ®Google Scholar
• Mo L, Pospichalova V, Huang Z, et al. Ascites increases expression/function of multidrug resistance proteins in ovarian cancer cells. PLoS ONE. 2015;10:e0131579.
   PubMed Web of Science ®Google Scholar
• Dorn J, Magdolen V, Gkazepis A, et al. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival. Ann Oncol. 2011;22:1783–1790.
   PubMed Web of Science ®Google Scholar
• Bronger H, Singer J, Windmüller C, et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer. 2016;115:553–563.
   PubMed Web of Science ®Google Scholar
• Teng PN, Wang G, Hood BL, et al. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer. 2014;110:123–132.
   PubMed Web of Science ®Google Scholar
• Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694–1706.
   PubMed Web of Science ®Google Scholar
• De Luca P, De Siervi A. Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis. Front Biosci (Elite Ed). 2016;8:72–83.
   PubMedGoogle Scholar
• Carey LA. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol. 2010;28:361–363.
   PubMed Web of Science ®Google Scholar
• Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998;58:1120–1123.
   PubMed Web of Science ®Google Scholar
• Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221–6228.
   PubMed Web of Science ®Google Scholar
• Dann RB, DeLoia JA, Timms KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125:677–682.
   PubMed Web of Science ®Google Scholar
• Carser JE, Quinn JE, Michie CO, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol. 2011;123:492–498.
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. JCO. 2012;30:2654–2663.
   PubMed Web of Science ®Google Scholar
• Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013;108:1231–1237.
   PubMed Web of Science ®Google Scholar
• Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. JCO. 2011;29:3008–3015.
   PubMed Web of Science ®Google Scholar
• Gunn S, Reveles X, Weldon K, et al. Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer. J Ovarian Res. 2013;6:2.
   PubMed Web of Science ®Google Scholar
• Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol. 2003;8:156–161.
   PubMedGoogle Scholar
• Sun S, Cai J, Yang Q, et al. Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis. PLoS ONE. 2016;11:e0166058.
   PubMed Web of Science ®Google Scholar
• Gonzalez Bosquet J, Newtson AM, Chung RK, et al. Prediction of chemo-response in serous ovarian cancer. Mol Cancer. 2016;15:66.
   PubMed Web of Science ®Google Scholar
• Perumal M, Stronach EA, Gabra H, et al. Evaluation of 2-deoxy-2-[18F]fluoro-d-glucose- and 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer. Mol Imaging Biol. 2012;14:753–761.
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Yamamoto Y, Kanenishi K, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging. 2008;35:287–295.
   PubMed Web of Science ®Google Scholar
• Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. JCO. 2005;23:7445–7453.
   PubMed Web of Science ®Google Scholar
• Kitajima K, Murakami K, Sakamoto S, et al. Present and future of FDG-PET/CT in ovarian cancer. Ann Nucl Med. 2011;25:155–164.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103:512–517.
   PubMed Web of Science ®Google Scholar
• Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010;119:484–490.
   PubMed Web of Science ®Google Scholar
• Holtz DO, Krafty RT, Mohamed-Hadley A, et al. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med. 2008;6:2.
   PubMed Web of Science ®Google Scholar
• Hurteau JA, Brady MF, Darcy KM, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;119:444–450.
   PubMed Web of Science ®Google Scholar
• Chambers SK, Clouser MC, Baker AF, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010;16:5320–5328.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Walker AJ, Minasian L, et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res. 2010;16:664–672.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Parker GJ, Mullamitha S, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. JCO. 2005;23:973–981.
   PubMed Web of Science ®Google Scholar
• Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res. 2013;19:5227–5239.
   PubMed Web of Science ®Google Scholar
• Backen A, Renehan AG, Clamp AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014;20:4549–4558.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Armaiz Pena GN, et al. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015;34:19–40.
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Brandslund I, et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010;117:109–116.
   PubMed Web of Science ®Google Scholar
• Lose F, Nagle CM, O'Mara T, et al. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol. 2010;119:479–483.
   PubMed Web of Science ®Google Scholar
• Goode EL, Maurer MJ, Sellers TA, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res. 2010;16:995–1007.
   PubMed Web of Science ®Google Scholar
• Smerdel MP, Steffensen KD, Waldstrøm M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol. 2010;118:167–171.
   PubMed Web of Science ®Google Scholar
• Schultheis AM, Lurje G, Rhodes KE, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14:7554–7563.
   PubMed Web of Science ®Google Scholar
• Chan JK, Kiet TK, Blansit K, et al. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. Gynecol Oncol. 2014;133:568–574.
   PubMed Web of Science ®Google Scholar
• O'Connor JP, Jackson A, Parker GJ, et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012;9:167–177.
   PubMed Web of Science ®Google Scholar
• Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014;30:326–339.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137–1154.
   PubMed Web of Science ®Google Scholar
• McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014;371:1725–1735.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Nakagomi H, Sakamoto I, et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med. 2015;3:121–129.
   PubMedGoogle Scholar
• Strom CM, Rivera S, Elzinga C, et al. Development and validation of a next-generation sequencing assay for BRCA1 and BRCA2 variants for the clinical laboratory. PLoS One. 2015;10:e0136419.
   PubMed Web of Science ®Google Scholar
• Weren RD, Mensenkamp AR, Simons M. Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum Mutat. 2017;38:226–235.
   PubMed Web of Science ®Google Scholar
• Hiatt JB, Pritchard CC, Salipante SJ, et al. Single molecule molecular inversion probes for targeted, high-accuracy detection of low frequency variation. Genome Res. 2013;23:843–854.
   PubMed Web of Science ®Google Scholar
• Walsh CS. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015;137:343–350.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–861.
   PubMed Web of Science ®Google Scholar
• Kristleit RSE, Oza A, Coleman RL, et al. Final results of ARIEL2 (Part 1): a phase 2 trial to prospectively identify ovarian cancer responders to rucaparib using tumor genetic analysis. European Cancer Conference. Vienna, Austria; 2015.
   Google Scholar
• Stover EH, Konstantinopoulos PA, Matulonis UA, et al. Biomarkers of response and resistance to DNA repair targeted therapies. Clin Cancer Res. 2016;22:5651–5660.
   PubMed Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764–3773.
   PubMed Web of Science ®Google Scholar
• Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41:210–220.
   PubMed Web of Science ®Google Scholar
• Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci. 2012;69:223–245.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Li J, Burger A, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. Clin Cancer Res. 2016;22:3227–3237.
   PubMed Web of Science ®Google Scholar
• Zaremba T, Thomas HD, Cole M, et al. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J. 2011;436:671–679.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu G, Xue F, et al. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol. 2016;141:57–64.
   PubMed Web of Science ®Google Scholar
• Lee JM, Gordon N, Trepel JB, et al. Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer. J Transl Med. 2015;13:239.
   PubMed Web of Science ®Google Scholar
• Dorn J, Bronger H, Kates R, et al. OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. Oncol Lett. 2015;9:418–424.
   PubMed Web of Science ®Google Scholar
• Dorn J, Beaufort N, Schmitt M, et al. Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. Crit Rev Clin Lab Sci. 2014;51:63–84.
   PubMed Web of Science ®Google Scholar
• Rodriguez N, Rauh-Hain JA, Shoni M, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125:362–366.
   PubMed Web of Science ®Google Scholar
• Kolomeyevskaya N, Eng KH, Khan AN, et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015;138:352–357.
   PubMed Web of Science ®Google Scholar
• Fagö-Olsen CL, Ottesen B, Christensen IJ, et al. Biomarkers for predicting complete debulking in ovarian cancer: lessons to be learned. Anticancer Res. 2014;34:679–682.
   PubMed Web of Science ®Google Scholar
• Abdallah R, Chon HS, Bou Zgheib N, et al. Prediction of optimal cytoreductive surgery of serous ovarian cancer with gene expression data. Int J Gynecol Cancer. 2015;25:1000–1009.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li L. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumour Biol. 2016;37:14765–14772.
   PubMed Web of Science ®Google Scholar
• Ataseven B, du Bois A, Reinthaller A, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138:560–565.
   PubMed Web of Science ®Google Scholar
• Angioli R, Capriglione S, Aloisi A, et al. A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (SeC-Score): a single-centre, controlled study for preoperative patient selection. Ann Surg Oncol. 2015;22:4217–4223.
   PubMed Web of Science ®Google Scholar
• Harter P, Beutel B, Alesina PF, et al. Prognostic and predictive value of the arbeitsgemeinschaft gynaekologische onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol. 2014;132:537–541.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532–1540.
   PubMed Web of Science ®Google Scholar
• Gasimli K, Braicu EI, Richter R, et al. Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer. Ann Surg Oncol. 2015;22:2729–2737.
   PubMed Web of Science ®Google Scholar
• Rutten IJ, van de Laar R, Kruitwagen RF, et al. Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: an external validation study of three models using computed tomography. Gynecol Oncol. 2016;140:22–28.
   PubMed Web of Science ®Google Scholar
• Barber EL, Rutstein S, Miller WC, et al. A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery. Gynecol Oncol. 2015;139:401–406.
   PubMed Web of Science ®Google Scholar
• Schwarz JK, Grigsby PW, Dehdashti F, et al. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009;50 Suppl 1:64S–73S.
   PubMed Web of Science ®Google Scholar
• Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17–22.
   PubMed Web of Science ®Google Scholar
• Shah CA, Allison KH, Garcia RL, et al. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109:215–219.
   PubMed Web of Science ®Google Scholar
• Vallius T, Hynninen J, Auranen A, et al. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. Tumour Biol. 2017;39:1010428317691189. doi:10.1177/1010428317691189
   PubMed Web of Science ®Google Scholar
• Qayyum A, Coakley FV, Westphalen AC, et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 2005;96:301–306.
   PubMed Web of Science ®Google Scholar
• Salani R, Axtell A, Gerardi M, et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2008;108:271–275.
   PubMed Web of Science ®Google Scholar
• Yeung TL, Leung CS, Yip KP, et al. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309:C444–C456.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Auer M, Ulz P, et al. Circulating tumor cells and DNA as liquid biopsies. Genome Med. 2013;5:73.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017. doi: 10.1038/nrclinonc.2017.14.
   PubMed Web of Science ®Google Scholar
• Broersen LHA, van Pelt GW, Tollenaar RAEM, et al. Clinical application of circulating tumor cells in breast cancer. Cell Oncol (Dordr). 2014;37:9–15.
   PubMed Web of Science ®Google Scholar
• Van Berckelaer C, Brouwers AJ, Peeters DJE, et al. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Eur J Surg Oncol. 2016;42:1772–1779.
   PubMed Web of Science ®Google Scholar
• Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol Oncol. 2017. pii: S0090-8258(17)30163-4. doi: 10.1016/j.ygyno.2017.02.042.
   Web of Science ®Google Scholar
• Liu JF, Kindelberger D, Doyle C, et al. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013;131:352–356.
   PubMed Web of Science ®Google Scholar
• Judson PL, Geller MA, Bliss RL, et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003;91:389–394.
   PubMed Web of Science ®Google Scholar
• Marth C, Kisic J, Kaern J, et al. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002;94:707–712.
   PubMed Web of Science ®Google Scholar
• Pearl ML, Zhao Q, Yang J, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol Oncol. 2014;134:581–590.
   PubMed Web of Science ®Google Scholar
• Pearl ML, Dong H, Tulley S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs). Gynecol Oncol. 2015;137:229–238.
   PubMed Web of Science ®Google Scholar
• Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014;60:1282–1289.
   PubMed Web of Science ®Google Scholar
• Aktas B, Kasimir-Bauer S, Heubner M, et al. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer. 2011;21:822–830.
   PubMed Web of Science ®Google Scholar
• Cui L, Kwong J, Wang CC. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. J Ovarian Res. 2015;8:38.
   PubMed Web of Science ®Google Scholar
• Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 2011;122:567–572.
   PubMed Web of Science ®Google Scholar
• Obermayr E, Castillo-Tong DC, Pils D, et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the OVCAD consortium. Gynecol Oncol. 2013;128:15–21.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bian B, Yuan X, et al. Prognostic value of circulating tumor cells in ovarian cancer: a meta-analysis. PLoS One. 2015;10:e0130873.
   PubMed Web of Science ®Google Scholar
• Zeng L, Liang X, Liu Q, et al. The predictive value of circulating tumor cells in ovarian cancer: a meta analysis. Int J Gynecol Cancer. 2015;17. doi: 10.1097/IGC.0000000000000459.
   Web of Science ®Google Scholar
• Su Y, Zheng L, Wang Q, et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res. 2010;29:27.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lankes HA, et al. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:86–91.
   PubMed Web of Science ®Google Scholar
• Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;123:19–26.
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Madsen CV, Andersen RF, et al. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. Eur J Cancer. 2014;50:2611–2618.
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Terlikowski SJ, Kinalski M, et al. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann Oncol. 2011;22:1133–1140.
   PubMed Web of Science ®Google Scholar
• Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13:e1002198.
   PubMed Web of Science ®Google Scholar
• Taucher V, Mangge H, Haybaeck J. Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cell Oncol (Dordr). 2016;39:295–318.
   PubMed Web of Science ®Google Scholar
• Vitiello M, Tuccoli A, Poliseno L. Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol. 2015;38:17–28.
   PubMed Web of Science ®Google Scholar
• Ayaz L, Çayan F, Balci Ş, et al. Circulating microRNA expression profiles in ovarian cancer. J Obstet Gynaecol. 2014;34:620–624.
   PubMedGoogle Scholar
• Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15:48.
   PubMed Web of Science ®Google Scholar
• Wan WN, Zhang YQ, Wang XM, et al. Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer. Diagn Pathol. 2014;9:178.
   PubMed Web of Science ®Google Scholar
• Eitan R, Kushnir M, Lithwick-Yanai G, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol. 2009;114:253–259.
   PubMed Web of Science ®Google Scholar
• Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008;68:10307–10314.
   PubMed Web of Science ®Google Scholar
• Zhu T, Gao W, Chen X, et al. A pilot study of circulating microRNA-125b as a diagnostic and prognostic biomarker for epithelial ovarian cancer. Int J Gynecol Cancer. 2017;27:3–10.
   PubMed Web of Science ®Google Scholar
• Meng X, Müller V, Milde-Langosch K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7:16923–16935.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013;8:e77853.
   PubMed Web of Science ®Google Scholar
• Benson EA, Skaar TC, Liu Y, et al. Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study. PLoS One. 2015;10:e0141279.
   PubMed Web of Science ®Google Scholar
• Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111:478–486.
   PubMed Web of Science ®Google Scholar
• Lu L, Schwartz P, Scarampi L, et al. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol. 2011;122:366–371.
   PubMed Web of Science ®Google Scholar
• Laios A, O'Toole S, Flavin R, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.
   PubMed Web of Science ®Google Scholar
• Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA. 2013;110:9845–9850.
   PubMed Web of Science ®Google Scholar
• Parikh A, Lee C, Joseph P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition. Nat Commun. 2014;5:2977.
   PubMed Web of Science ®Google Scholar